Member Info for miavoce

Exactly. Somebody hitting the bid with sequence of chunky blocks to move the price, knowing that PI's will then panic sell and move the price further down, all very professional IMO.

Someone clearly wants the price back down. Maybe preparing for the next round of buying. SP being moved around very professionally.

Hi Smithfield's,

if you look back through the RNS's you will see that the money was raised for the following purposes (i.e. largely to support the activities needed to continue growing the business):-

o £2.8 million for staff and next generation sequencing resources to develop molecular assay content providing data and new downstream applications for the Parsortix system;

o £2.2 million for commercial business development through salesforce and distributor expansion, further distributor onboarding, product launches, conferences and marketing;

o £1.5 million towards developing the clinical laboratory capability and capacity including molecular capital expenditure and protocol validation, staffing and expansion of service offering

o £2m shall be used by the Company to strengthen the balance sheet, enhance the working capital position and cover the expenses associated with the Fundraise

EC, I understand from AN's previous presentation that they are talking to multiple pharma's. Be patient.

There is clearly value in CTC's Moab but the area is so new that most pharma won't have investigate the subject as yet. It will take time for the market to establish itself, slowly at first (as now) but accelerating as the benefits become more widely known. Angle will grow, slow at first (as now) and the growth will then gradually accelerate until it becomes a juggernaut.

Trading normally fizzles out about now and a few sells may move the bid back to 19p. And then tomorrow will be the same cycle and today, and the day before....

Spreadex now stopped buy spreadbets - must be no stock around.

Well that is todays 0.5p in the bag. On to tomorrow now.

...sorry, should have added that the interim approval would come into play because SCIB1/iSCIB1+ would be addressing a significant unmet need.

Hi Ivy, you mention 2030/31 as timeline for approval. I have heard mention of interim approval if the early P3 results are good (possibly this has been mentioned by LD herself but I'm not certain on that) - I presume this would be several years earlier than 2030/31 ?

Having excellent SCIB1 results first, followed by a break and then even better iSCIBi+ results, is the optimum path for the share price. It would be like a pinball machine where the ball hits one of the kickers and then as it loses speed from the first kicker, hits another kicker.

In the last 5 years both times we have reached 18p we have gone to 27p and then stopped. 3rd time lucky to break 27p ?

Plenty of blues now. Looking strong into the close.

If we can break through 17p, which has provided resistance a number of times over the years, we should be well set for new all time high as the next weeks / months progress.

Huge buy from 13:25 just reported (buy price at the time was 16p). MM's must be getting very stretched for stock.

Cleary whoever is behind this buying really wants to avoid a spike in the price (which is what would happen if the herd turns up). Probably trying to get as many shares as possible as cheaply as they can before news breaks.

Two things to love about his rise:-

1. It appears that the price is being deliberately and calmly walked up very professionally. Not so fast that the herd are drawn to it but nonetheless a very substantial rise. I saw this once before a few years ago (can't remember the share) and the rise not only stuck but it preceded some significant corporate action.

2. There appear to be no sellers despite the rising price. It is as though every holder knows that the company is about to produce results that will blow the current share price out of the water.

...and raising the bid is not generating any meaningful selling. Looks like most folks know what is coming and aren't willing to exit cheaply. Makes a nice change.

Having had a few days for it to sink in, here are some further thoughts on the recent RNS>

1. The latest RNS title and content referred to the ‘iSCIB1+ Clinical Advisory Meeting’. This appears to telling us that iSCIB1+ has been selected has the version to be taken forward into the phase 2/3.

2. The RNS also tells us that 22/43 patients have been recruited into the iSCIB1+ cohort of the trial. Not all of these recruits will have had their first scan as yet - perhaps half of them ?. The decision to move forward with iSCIB1+ with relatively few scanned patients implies to me that the results from those scanned so far must be very impressive indeed in order for the Advisory Board have such confidence.

3. The comment about the overwhelming interest in the poster, together with the nature of the attendees, must also have been put there for a reason - perhaps to tell us (without telling us) that there is pharma / commercial interest being expressed.

Maybe it is a bit like advertising...something has to be repeated to people many times before it registers with them. Perhaps the cumulative effect of the presentations at numerous conferences had the same effect which culminated in the ASCO interest.